Scholarlink

Objective <p>To evaluate whether the effect of late surfactant is modified by patent ductus arteriosus (PDA) status with respect to survival without bronchopulmonary dysplasia (BPD) in ventilated infants born &lt;28 weeks’ gestation.</p> Methods <p>Secondary analysis of the Trial of Late Surfactant (TOLSURF). A formal test of interaction between PDA presence and late surfactant, with respect to survival without BPD at 36 and 40 weeks’ postmenstrual age (PMA), was performed. PDA presence was defined by PDA treatment, either medical or a ligation (definition A), or PDA ligation (definition B), during or after late surfactant administration.</p> Results <p>All 511 infants were included. No interaction was detected between a PDA and late surfactant for survival without BPD at 36 weeks’ PMA (definition A: <i>p</i> = 0.41; definition B: <i>p</i> = 0.33), or at 40 weeks’ PMA (definition A: <i>p</i> = 0.84; definition B: <i>p</i> = 0.42).</p> Conclusion <p>PDA presence did not modify the effect of late surfactant for survival without BPD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect modification of late surfactant treatment by patent ductus arteriosus status in ventilated preterm infants: a secondary analysis of a randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月20日

查看全文
  • Patrick J. Peebles,
  • Jens C. Eickhoff,
  • Timothy G. Elgin,
  • Anudeepa Sharma,
  • Nicolas A. Bamat,
  • Jonathan M. Klein,
  • Patrick J. McNamara,
  • Roberta L. Keller,
  • Dinushan C. Kaluarachchi

摘要

Objective

To evaluate whether the effect of late surfactant is modified by patent ductus arteriosus (PDA) status with respect to survival without bronchopulmonary dysplasia (BPD) in ventilated infants born <28 weeks’ gestation.

Methods

Secondary analysis of the Trial of Late Surfactant (TOLSURF). A formal test of interaction between PDA presence and late surfactant, with respect to survival without BPD at 36 and 40 weeks’ postmenstrual age (PMA), was performed. PDA presence was defined by PDA treatment, either medical or a ligation (definition A), or PDA ligation (definition B), during or after late surfactant administration.

Results

All 511 infants were included. No interaction was detected between a PDA and late surfactant for survival without BPD at 36 weeks’ PMA (definition A: p = 0.41; definition B: p = 0.33), or at 40 weeks’ PMA (definition A: p = 0.84; definition B: p = 0.42).

Conclusion

PDA presence did not modify the effect of late surfactant for survival without BPD.